Shin OS. Insight into the pathogenesis of Lyme Disease [J]. J Virol,2014,44(1):10-22.
[3]
Bhattacharya D, Bensaci M, Luker KE,et al. Development of a baited oral vaccine for use in reservoir-targeted strategies against Lyme Dis- ease [J]. Vaccine, 2011,29(44):7818-7825.
Bao FK ,Fikrig E. The pathogen-vector-host interactions during Bor-relia burgdorferi transmission [J].Chinese Journal of Vector Biologyand Control, 2008,19(3)：264-268.
[11]
Lewandowski D,Urbanowicz A,Figlerowicz M,et al. Functional in-sights into recombinant TROSPA protein from Ixodes ricinus [J].PLoS One,2013,8(10):e76848.
[12]
Li H, Dunn JJ, Luft BJ,et al. Crystal structure of Lyme disease antigen outer surface protein A complexed with an Fab [J]. Proc Natl AcadSci USA,1997,94(8)：3584-3589.
[13]
Kitahara R, Simorellis AK, Hata K, et al. A delicate interplay of struc-ture, dynamics, and thermodynamics for function: a high pressureNMR study of outer surface protein A [J]. Biophys J,2012,102(4):916-926.
Templeton TJ. Borrelia outer membrane surface proteins and transmis-sion through the tick [J].J Exp Med, 2004,199(5):603-606.
[16]
Cervantes JL,Hawley KL, Benjamin SJ,et al. Phagosomal TLR signal-ing upon Borrelia burgdorferi infection [J]. Cellular and Infection Mi-crobiology, 2014,4:00055.
[17]
Hayes BM,Dulebohn DP,Sarkar A,et al. Regulatory protein BBD18 of the Lyme Disease spirochete: essential role during tick acquisition?[J].MBio,2014,5(2):e01017.
[18]
He M,Oman T,Xu H,et al. Abrogation of ospAB constitutively acti-vates the Rrp2-RpoN-RpoS pathway (sigmaN-sigmaS cascade) in Borrelia burgdorferi [J].Mol Microbiol, 2008,70(6):1453-1464.
[19]
Schmit VL, Patton TG, Gilmore RD.Analysis of Borrelia burgdorferi surface proteins as determinants in establishing host cell interactions [J]. Front Microbiol,2011,2:141.
[20]
Toledo A, Crowley JT, Coleman JL,et al. Selective association of outer surface lipoproteins with the lipid rafts of Borrelia burgdorferi [J]. MBio. 2014,5(2):e00899China Tropical Medicine,February 2015,Vol.15,No.02
[21]
Hübner A, Yang X, Nolen D M, et al. Expression of Borrelia burgdor-feri OspC and DbpA is controlled by a RpoN-RpoS regulatory path-way [J]. Proc Natl Acad Sci USA, 2001, 98(22): 12724-12729.
[22]
Wilske B, Preac-Mursic V, Göbel UB,et al. An OspA serotyping sys-tem for Borrelia burgdorferi based on reactivity with monoclonal anti-bodies and OspA sequence analysis [J]. J Clin Microbiol,1993 ,31(2):
[23]
340-350.
[24]
Rosef O,Radzijevskaja J,Klccker L,et al. The prevalence of Borrelia burgdorferi sensu lato in questing Ixodes ricinus ticks in Norway [J]. Biologija,2014,60(1):33-45.
[25]
Masuzawa T, Wilske B, Komikado T,et al. Comparison of OspA sero-types for Borrelia burgdorferi sensu lato from Japan, Europe and North America [J].Microbiol Immunol, 1996,40(8):539-545.
Schmidt BL.PCR in laboratory diagnosis of Human Borrelia burgdor- feri infection [J]. Clin Microbiol Rev,1997,10(1):185-201.
[28]
Liu ZY, Hao Q, Hou XX,et al. A study of the technique of Western Blot for diagnosis of Lyme disease caused by Borrelia afzelii in China [J]. Biomed Environ Sci,2013,26(3):190-200.
[29]
Donta ST. Issues in the diagnosis and treatment of Lyme Disease [J].Open Neurol J, 2012,6:140-145.
[30]
Molins CR, Sexton C, Young JW,et al. Collection and Characterization of Samples for the Establishment of a Serum Repository for Lyme Dis-ease Diagnostic Test Development and Evaluation [J]. J Clin Microbi-ol,2014,13. pii: JCM,1409-1414.
[31]
Lewandowski D,Urbanowicz A,Figlerowicz M.The fruitful coexistrncen of Borrelia burgdorferi and Ixodex ticks [J].Bio Technologia,2013,91(1):31-33.
[32]
Schutzer SE, Coyle PK, Dunn JJ,et al. Early and specific antibody re-sponse to OspA in Lyme disease [J]. J Clin Invest,1994 ,94(1):454-457.
[33]
Eshoo MW, Crowder CC, Rebman AW. Direct molecular detection on and genotyping of Borrelia burgdorferi from whole blood of patients with early lyme disease [J]. PLoS One ,2012,7(5):e36825.
Sigal LH, Zahradnik JM, Lavin P, et al. A vaccine consisting of recom-binant Borrelia burgdorferi outer- surface protein A to prevent Lyme disease.Recombinant Outer- Surface Protein A Lyme Disease Vac-cine Study Consortium [J]. N Engl J Med.,1998 ,339(4):216-222.
[36]
Barrett PN, Portsmouth D. A novel multivalent OspA vaccine against Lyme Borreliosis shows promise in Phase I/II studies [J]. Expert Rev Vaccines,2013,12(9):973-975.
[37]
Dai J, Wang P, Adusumilli S,et al. Antibodies against a tick protein, Salp15, protect mice from the Lyme disease agent [J]. Cell Host Mi-crobe, 2009,6(5):482-492.
[38]
Wagner B, Freer H, Rollins A, et al.Antibodies to Borrelia burgdorferi OspA, OspC, OspF, and C6 antigens as markers for early and late in- fection in dogs [J]. Clin Vaccine Immunol,2012 ,19(4):527-535.
[39]
Fawcett PT, Rose CD, Maduskuie V.Long-term effects of immuniza- tion with recombinant lipoprotein outer surface protein A on serologic test for Lyme disease [J]. Clin Diagn Lab Immunol, 2004,11(4):808-810.
[40]
Livey I, O'Rourke M, Traweger A,et al. A new approach to a Lyme dis-ease vaccine[J]. Clin Infect Dis, 2011 ,52 (3):266-270.
[41]
Del Rio B, Seegers JF, Gomes SM. Immune response to lactobacillus plantarum expressing Borrelia burgdorferi OspA is modulated by the lipid modification of the antigen [J]. PLoS One,2010,5(6): e111999
[42]
Barrett PN, Portsmouth D. The need for a new vaccine against Lyme borreliosis [J]. Expert Rev Vaccines ,2013,12(2):101-103.
[43]
Hilton E, Devoti J, Sood S.Recommendation to include OspA and Os-pB in the new immunoblotting criteria for serodiagnosis of Lyme dis-ease [J]. J Clin Microbiol, 1996 ,34(6):1353-1354.
